Health Care [ 8/12 ] | Biotechnology [ 49/73 ]
NASDAQ | Common Stock
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors.
Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 25 | -0.29 Increased by +12.12% | -0.34 Increased by +14.71% |
| May 7, 25 | -0.32 Increased by +31.91% | -0.38 Increased by +15.66% |
| Feb 24, 25 | -0.44 Increased by +2.22% | -0.42 Decreased by -3.82% |
| Nov 6, 24 | -0.40 Increased by +13.04% | -0.41 Increased by +2.96% |
| Aug 13, 24 | -0.33 Increased by +38.89% | -0.48 Increased by +31.25% |
| May 9, 24 | -0.47 Decreased by -147.37% | -0.49 Increased by +4.08% |
| Feb 26, 24 | -0.45 Increased by +22.41% | -0.52 Increased by +13.46% |
| Nov 8, 23 | -0.46 Increased by +46.51% | -0.57 Increased by +19.30% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 1.91 M Decreased by -71.84% | -34.07 M Increased by +11.34% | Decreased by -1.79 K% Decreased by -214.85% |
| Mar 31, 25 | 1.63 M Decreased by -15.38% | -37.62 M Increased by +21.63% | Decreased by -2.31 K% Increased by +7.39% |
| Dec 31, 24 | 1.86 M Increased by +10.98% | -52.15 M Decreased by -18.20% | Decreased by -2.80 K% Decreased by -6.51% |
| Sep 30, 24 | 3.07 M Increased by +58.13% | -47.68 M Decreased by -5.55% | Decreased by -1.55 K% Increased by +33.25% |
| Jun 30, 24 | 6.77 M Increased by +625.83% | -38.43 M Increased by +27.16% | Decreased by -567.44% Increased by +89.96% |
| Mar 31, 24 | 1.93 M Decreased by -96.74% | -48.00 M Decreased by -423.49% | Decreased by -2.49 K% Decreased by -15.94 K% |
| Dec 31, 23 | 1.68 M Decreased by -96.22% | -44.12 M Increased by +8.66% | Decreased by -2.63 K% Decreased by -2.32 K% |
| Sep 30, 23 | 1.94 M Decreased by -87.02% | -45.17 M Increased by +44.05% | Decreased by -2.32 K% Decreased by -331.15% |